Table 1.
Patient Characteristics (N = 180)
| Characteristic | N (%) Value |
|---|---|
| Age, median (range) | 32 (17–65) |
| Male/female | 106/74 |
| HDC regimen | |
| Gem-Bu-Mel | 84 |
| BEAM | 57 |
| Bu-Mel | 39 |
| Front-line chemotherapy | |
| ABVD | 176 (98%) |
| Stanford-V | 3 (1.5%) |
| Other | 1 (0.5%) |
| First-line salvage therapy | 180 |
| ICE | 101 (56%) |
| ESHAP | 54 (30%) |
| 1GEV | 25 (14%) |
| Second-line salvage therapy | 78 |
| GND | 26 (33%) |
| IGEV | 24 (31%) |
| ICE | 20 (26%) |
| Other | 8 (10%) |
| Third-line salvage therapy or beyond | 45 |
| GND | 18 (34%) |
| IGEV | 17 (32%) |
| ICE | 8 (14%) |
| Other | 10 (19%) |
| Radiation with initial treatment | 52 (29%) |
| First remission | |
| Primary induction failure | 86 (48%) |
| 3–6 mo | 50 (28%) |
| 6–12 mo | 17 (9%) |
| >12 mo | 27 (15%) |
| Relapse within prior radiation field | 22 (12%) |
| Number of salvage regimens, median (range) | 1 (1–5) |
| 1 | 119 (66%) |
| >1 | 61 (34%) |
| Extranodal disease at relapse/PD | 72 (40%) |
| B symptoms at relapse/PD | 21 (12%) |
| Bulky disease at relapse/PD | 55 (30%) |
| PET at HDC | 175 (97%) |
| Negative | 106 (62%) |
| After first salvage line | 72 (41%) |
| After second salvage line | 25 (15%) |
| After third salvage line or beyond | 9 (5%) |
| Positive | 69 (38%) |
| After response to first salvage | 22 (12%) |
| After response to second salvage or beyond | 22 (12%) |
| No response to prior line | 26 (14%) |